Overview

Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts

Status:
Recruiting
Trial end date:
2025-10-23
Target enrollment:
Participant gender:
Summary
2.1. General To evaluate the efficacy and safety of a Cannabis sativa extract (CBD (Cannabidiol) + up to 0.3% THC (Delta-9-tetrahydrocannabinol)), compared to placebo, in the treatment of cocaine/crack use disorder. 2.2. Specifics - Compare the amount and frequency of cocaine use between the group treated with Cannabis sativa extract and the placebo group - Compare adherence to treatment between the group treated with Cannabis sativa extract and the placebo group - Evaluate the prevalence and intensity of depressive and anxious symptoms in patients using Cannabis sativa extract compared to patients using placebo - Evaluate the incidence and severity of side effects in the active group compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
University of Sao Paulo General Hospital